

European Society for Clinical Virology
(Limited by guarantee)

Report and Financial Statements
for the year ended 31 October 2024

Members of Executive - Company Directors
(November 1st 2023 - October 31st 2024)

Prof. Dr. Pamela Vallely (President)
Prof. Dr. Mariet C.W. Feltkamp (Past President)
Prof. Dr. Annelies Riezebos-Brilman (Vice President)
Prof. Dr. Maria São José Alexandre Nascimento (Vice President)
Prof. Dr. Catherine Moore (General Secretary)
Prof. Dr. Xavier López-Labrador (Communication Officer)
Prof. Dr. George Sourvinos (Treasurer)
Prof. Dr. Heli Harvala (Meetings Secretary)

Company Secretary

Ester Zoroa, Kenes Group, KAM

European Society for Clinical Virology (ESCV) details

Registered Office
Charles Darwin House
12 Roger Street
London

Company limited by guarantee
N° 04620455

Registered as a Charity in England
N° 1099537

Inland Revenue reference:
610 94961 19846 A 01

Directors' Report

The European Society for Clinical Virology (ESCV) is a Company Limited by Guarantee, first incorporated in 2003. In accordance with the Society's Memorandum of Association, each Company Member undertakes to contribute such amount as may be required, not exceeding £1, to the Company's assets if it should be wound up while he or she is a Company Member or within one year after he or she ceases to be so.

The Society is registered as a Charity, the Company Directors being the Charity's Trustees.

The Company Directors acting collectively are the Society's Executive.

The Executive hereby submits its report and financial statements for the year ending October 31st, 2024.

Organization and Objectives

According to the articles, the Society is administered by the Executive, made up of minimum three and maximum ten Company Directors/Charity Trustees. Currently the Executive numbers eight Directors.

The ESCV has appointed a professional secretariat to handle administrative matters. This secretariat is Kenes Group, Rue François-Versonnex 7, 1207 Geneva, Switzerland.

In accordance with Article 4 the Executive admits as 'ESCV Members' such persons and subjects them to such rights and obligations as it thinks fit. Such 'ESCV Members' are not Company Members for the purposes of the Articles and are not entitled to vote on any matter save where expressly provided in the Articles.

ESCV members of different European and other countries are represented by councilors, elected by each country's members according to procedures described in the Articles. The councilors acting collectively are the Council. The Council elects the Company Directors/Charity Trustees according to procedures described in the Articles.

The Society's objectives are to promote public health and to advance public education, in particular medical education, by:

- improving the knowledge of viruses, particularly as it relates to the diagnosis and management of viral diseases, their pathogenesis, natural history and prevention.
- improving diagnostic methods.
- promoting high standards in laboratory viral diagnosis through quality assessment activities and education; and
- promoting or developing for the benefit of the public the preparation and exchange of reference reagents.

Reserves Policy

The Executive has the policy to maintain sufficient funds to allow the Society to meet its objectives and obligations on a long-term basis, and to provide a measure of investment income. It is the objective of the Society to utilize fully each year's net income for its charitable activities.

Review of Activities in 2023/2024

Scientific Meetings

- NGS workshop, 23rd and 24th January 2023. London (UK).
- ESCV – ECCI workshop on Congenital CMV Infection, 26th and 27th April 2023. Crete (Greece).
- 25th Annual Conference of the ESCV, 30th August – 2nd of September 2023 Milan (Italy).
- European Non-Polio Enterovirus Network (ENPEN) on Non-Polio Enteroviruses in Europe workshop, took place from 23-24 May 2024, in Corfu, Greece.
- 4th ESCV workshop on Next Generation Sequencing in Clinical Virology, took place from the 10 – 11 June 2024 in Stockholm, Sweden.
- 26th Annual Conference of the ESCV, 17-21st of September 2024 Frankfurt, Germany.

Awards given at the 26th Annual Conference of the European Society for Clinical Virology 2024 (Frankfurt)

- European Diagnostic Virology (former Abbott Award) 2024 to Dr. Julianne Brown.
- BioMerieux Award 2024 to Prof. Mariet Feltkamp.
- Gardner Lectureship Award 2024 to Dr. Hans Hellmuth Hirsch.
- Heine-Medin Award 2024 to Dr. Emma Hodcrof

Travel grants and fellowships given

- 22 virologists received a grant to attend the 26th Annual Conference of the European Society for Clinical Virology

Training grants

- None

Business Meetings held

- ESCV Executive Meetings were held on 24th of January, 22nd of February, 25th of March, 22nd of April, 24th of May, 27th of June, 25th of July, 18th of September, 24th of October, 28th of November and 16th of December 2024.
- Council Meeting was held on 19th of September 2024.
- General Assembly was held on 20th of September 2024.

Future Scientific Meetings planned

- 27th Annual Conference of the ESCV, 17th – 20th of September 2025 (Thessaloniki, Greece).

Signed on behalf of the Executive (Company Directors),

A handwritten signature in black ink, appearing to read 'P Vallely', is enclosed within a thin black rectangular border.

Prof. Dr. Pam Vallely
Company President

Statement of financial activities (incorporating the income and expenditure account)

Year ended 31 October 2024

EUROPEAN SOCIETY FOR CLINICAL VIROLOGY, LONDON Balance sheet accounts as at October 31, 2024

	Notes	2024 EUR	2024 GBP 0.83430	2023 EUR	2023 GBP 0.87237
<u>ASSETS</u>					
Bank account	4	26'529	22'133	197'958	172'692
Debtor ECCI		6'392	5'333	-	-
		32'921	27'466	197'958	172'692
<u>LIABILITIES</u>					
Accounts payable		163	136	23'922	20'869
#		163	136	23'922	20'869
<u>GENERAL RESERVES</u>					
General reserves brought forward		174'036	151'823	318'476	273'220
Result of the year		-141'278	-117'868	-144'440	-126'005
Foreign exchange conversion		-	-6'625	-	4'608
		32'758	27'330	174'036	151'823
		32'921	27'466	197'958	172'692

EUROPEAN SOCIETY FOR CLINICAL VIROLOGY, LONDON
Income & Expenses accounts from 1 November 2023 to 31 October 2024

	Notes	2024 EUR	2024 GBP 0.83430	2023 EUR	2023 GBP 0.85790
<u>INCOMES</u>					
Membership fees		24'490	20'432	30'583	26'679
Sponsorship		10'500	8'760	5'618	4'901
Congress income	5	37'669	31'427	47'718	41'628
		72'659	60'619	83'919	73'208
<u>EXPENSES</u>					
Travel grants		51'546	43'005	84'578	73'783
Awards		10'500	8'760	-	-
Workshop expenses		89'340	74'536	91'469	79'795
Congress expenses		-	-	23'378	20'394
Project expenses		24'342	20'309		
Journal expenses		1'755	1'464	4'690	4'091
Administrative expenses		27'640	23'060	17'640	15'389
Bank charges		3'814	3'182	6'604	5'761
Extraordinary expenses	6	5'000	4'171	-	-
		213'937	178'487	228'359	199'213
Net loss of the year		-141'278	-117'868	-144'440	-126'005

Audit Exemption

(a) For the year ended 31 October 2024 the company was entitled to exemption from audit under section 477(2) of the Companies Act 2006 relating to small companies.

(b) Members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.

(c) The directors acknowledge their responsibility for:

i. ensuring the company keeps accounting records which comply with section 386; and
ii. preparing accounts which give a true and fair view of the state of affairs of the company as at the end of the financial year, and of its profit or loss for the financial year, in accordance with the requirements of section 393, and which otherwise comply with the requirements of the Companies Act relating to accounts, so far as applicable to the company.

(d) These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

Approved by Executive on 16th of July 2025 and signed on its behalf by Prof. Dr. Pam Vallely (Company President).



Prof. Pamela Vallely
Company President

This page is left blank intentionally (last page)

European Society for Clinical Virology

(Company limited by guarantee)

London - United Kingdom

Financial Statements

as at

31 October 2024

EUROPEAN SOCIETY FOR CLINICAL VIROLOGY, LONDON
Balance sheet accounts as at October 31, 2024

	Notes	2024 EUR	2024 GBP 0.83430	2023 EUR	2023 GBP 0.87237
<u>ASSETS</u>					
Bank account	4	26'529	22'133	197'958	172'692
Debtor ECCI		6'392	5'333	-	-
		32'921	27'466	197'958	172'692
<u>LIABILITIES</u>					
Accounts payable		163	136	23'922	20'869
#		163	136	23'922	20'869
<u>GENERAL RESERVES</u>					
General reserves brought forward		174'036	151'823	318'476	273'220
Result of the year		-141'278	-117'868	-144'440	-126'005
Foreign exchange conversion		-	-6'625	-	4'608
		32'758	27'330	174'036	151'823
		32'921	27'466	197'958	172'692

Pamela Vallely
 Authorized signature

PJ Vallely

GEORGIOS SOURVINOS
22/06/2025 19:28

Authorized signature

Date 26/06/25

Date _____

EUROPEAN SOCIETY FOR CLINICAL VIROLOGY, LONDON
Income & Expenses accounts from 1 November 2023 to 31 October 2024

	Notes	2024 EUR	2024 GBP 0.83430	2023 EUR	2023 GBP 0.85790
<u>INCOMES</u>					
Membership fees		24'490	20'432	30'583	26'679
Sponsorship		10'500	8'760	5'618	4'901
Congress income	5	37'669	31'427	47'718	41'628
		72'659	60'619	83'919	73'208
<u>EXPENSES</u>					
Travel grants		51'546	43'005	84'578	73'783
Awards		10'500	8'760	-	-
Workshop expenses		89'340	74'536	91'469	79'795
Congress expenses		-	-	23'378	20'394
Project expenses		24'342	20'309		
Journal expenses		1'755	1'464	4'690	4'091
Administrative expenses		27'640	23'060	17'640	15'389
Bank charges		3'814	3'182	6'604	5'761
Extraordinary expenses	6	5'000	4'171	-	-
		213'937	178'487	228'359	199'213
Net loss of the year		-141'278	-117'868	-144'440	-126'005

EUROPEAN SOCIETY FOR CLINICAL VIROLOGY, LONDON

Notes to the Accounts of October 31, 2024

1- GENERAL

EUROPEAN SOCIETY FOR CLINICAL VIROLOGY "ESCV", is registered as Charity under reference number 1099537.

The Private Limited Company by guarantee reference number is 04620455.

ESCV was incorporated on December 18, 2002.

The mission of ESCV is to provide a forum for virologists, scientists and physicians interested in all aspects of Clinical Virology and human viral diseases.

The registered office is at Charles Darwin House, 12 Roger Street, London WC1N 2JU, United Kingdom.

ESCV officers are :

- Pamela Josephine Vallely
- Catherine Moore
- Xavier Lopez Labrador
- Georgios Sourvinos
- Mariet Feltkamp
- Heli Harvala
- Maria Sao Jose Garcia Alexandre Naschimento

- Annelies Riezebos-Brilman

2 - AUDIT EXEMPTION

For the year ending 31 October 2024, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

3 – EMPLOYEES

No employees for this year.

4 – BANK ACCOUNT

Represent unrestricted cash balance in Euro held at BBVA Bank in Spain.

5 – CONGRESS INCOME

Income received for the ESCV meeting organised in 2023 in Milan.

6 – EXTRAORDINARY EXPENSES

The payment received on August 8th, 2022, was considered as sponsorship. This has been reclassified in deduction of the advance done to ECCI.



Section A

Independent Examiner's Report

Report to the trustees/
members of

Charity Name
European Society for Clinical Virology

On accounts for the year
ended

31st October 2024

Charity no
(if any)

1099537

Set out on pages

2

(remember to include the page numbers of additional sheets)

I report to the trustees on my examination of the accounts of the above charity ("the Trust") for the year ended **31/10 / 2024**.

Responsibilities and
basis of report

As the charity trustees of the Trust, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent
examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention (other than that disclosed below *) in connection with the examination which gives me cause to believe that in, any material respect:

- accounting records were not kept in accordance with section 130 of the Act or
- the accounts do not accord with the accounting records

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in order to enable a proper understanding of the accounts to be reached.

** Please delete the words in the brackets if they do not apply.*

Signed:

Date: May 9th 2025

Name:

Susanne Dudman

Relevant professional
qualification(s) or body
(if any):

Senior Medical Officer and Professor
Member ESCV

Address:

Oslo University Hospital, University of Oslo

P.O.Box 4950 Nydalen

0424 Oslo, Norway

Only complete if the examiner needs to highlight matters of concern (see CC32, Independent examination of charity accounts: directions and guidance for examiners).

Give here brief details of any items that the examiner wishes to disclose.

None.